Left atrial appendage devices for stroke prevention in atrial fibrillation

Sarah K. Hussain, Rohit Malhotra, John P. Dimarco

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is the most commonly encountered clinical arrhythmia, and stroke prevention remains an integral part of management of AF. Long-term therapy with oral anticoagulants, though effective, has many limitations, and these limitations have encouraged the search for device-based alternatives. In patients with non-valvular AF, approximately 90 % of thrombi are thought to arise from the left atrial appendage (LAA). The LAA can be obliterated surgically or percutaneously, and this should reduce the incidence of systemic thromboembolic events in AF, ideally without the need for further anticoagulation. We explore the currently available LAA occlusion devices and the evidence behind these devices. Although additional evidence from randomized trials is required to fully characterize the safety and efficacy of all of these devices, LAA occlusion has the potential to offer an attractive alternative for those at high stroke risk but are under-protected because of contraindications to anticoagulant therapy.

Original languageEnglish (US)
Pages (from-to)458-464
Number of pages7
JournalJournal of cardiovascular translational research
Volume7
Issue number4
DOIs
StatePublished - Jun 2014

Fingerprint

Atrial Appendage
Atrial Fibrillation
Stroke
Equipment and Supplies
Anticoagulants
Cardiac Arrhythmias
Thrombosis
Safety
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmaceutical Science
  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)

Cite this

@article{e9c51ef6c9d943dda888762d6b6a0624,
title = "Left atrial appendage devices for stroke prevention in atrial fibrillation",
abstract = "Atrial fibrillation (AF) is the most commonly encountered clinical arrhythmia, and stroke prevention remains an integral part of management of AF. Long-term therapy with oral anticoagulants, though effective, has many limitations, and these limitations have encouraged the search for device-based alternatives. In patients with non-valvular AF, approximately 90 {\%} of thrombi are thought to arise from the left atrial appendage (LAA). The LAA can be obliterated surgically or percutaneously, and this should reduce the incidence of systemic thromboembolic events in AF, ideally without the need for further anticoagulation. We explore the currently available LAA occlusion devices and the evidence behind these devices. Although additional evidence from randomized trials is required to fully characterize the safety and efficacy of all of these devices, LAA occlusion has the potential to offer an attractive alternative for those at high stroke risk but are under-protected because of contraindications to anticoagulant therapy.",
author = "Hussain, {Sarah K.} and Rohit Malhotra and Dimarco, {John P.}",
year = "2014",
month = "6",
doi = "10.1007/s12265-014-9565-5",
language = "English (US)",
volume = "7",
pages = "458--464",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "4",

}

Left atrial appendage devices for stroke prevention in atrial fibrillation. / Hussain, Sarah K.; Malhotra, Rohit; Dimarco, John P.

In: Journal of cardiovascular translational research, Vol. 7, No. 4, 06.2014, p. 458-464.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Left atrial appendage devices for stroke prevention in atrial fibrillation

AU - Hussain, Sarah K.

AU - Malhotra, Rohit

AU - Dimarco, John P.

PY - 2014/6

Y1 - 2014/6

N2 - Atrial fibrillation (AF) is the most commonly encountered clinical arrhythmia, and stroke prevention remains an integral part of management of AF. Long-term therapy with oral anticoagulants, though effective, has many limitations, and these limitations have encouraged the search for device-based alternatives. In patients with non-valvular AF, approximately 90 % of thrombi are thought to arise from the left atrial appendage (LAA). The LAA can be obliterated surgically or percutaneously, and this should reduce the incidence of systemic thromboembolic events in AF, ideally without the need for further anticoagulation. We explore the currently available LAA occlusion devices and the evidence behind these devices. Although additional evidence from randomized trials is required to fully characterize the safety and efficacy of all of these devices, LAA occlusion has the potential to offer an attractive alternative for those at high stroke risk but are under-protected because of contraindications to anticoagulant therapy.

AB - Atrial fibrillation (AF) is the most commonly encountered clinical arrhythmia, and stroke prevention remains an integral part of management of AF. Long-term therapy with oral anticoagulants, though effective, has many limitations, and these limitations have encouraged the search for device-based alternatives. In patients with non-valvular AF, approximately 90 % of thrombi are thought to arise from the left atrial appendage (LAA). The LAA can be obliterated surgically or percutaneously, and this should reduce the incidence of systemic thromboembolic events in AF, ideally without the need for further anticoagulation. We explore the currently available LAA occlusion devices and the evidence behind these devices. Although additional evidence from randomized trials is required to fully characterize the safety and efficacy of all of these devices, LAA occlusion has the potential to offer an attractive alternative for those at high stroke risk but are under-protected because of contraindications to anticoagulant therapy.

UR - http://www.scopus.com/inward/record.url?scp=84903736565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903736565&partnerID=8YFLogxK

U2 - 10.1007/s12265-014-9565-5

DO - 10.1007/s12265-014-9565-5

M3 - Article

C2 - 24789763

AN - SCOPUS:84903736565

VL - 7

SP - 458

EP - 464

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 4

ER -